Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 5Anemia 5Leukemia, Myelomonocytic, Chronic 4Anemia, Refractory, with Excess of Blasts 4Leukemia 3Thrombocytopenia 2Leukemia, Lymphocytic, Chronic, B-Cell 2Paraproteinemias 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1GATA2 Deficiency 1Fever 1Fatigue 1Anemia, Refractory 1Agammaglobulinemia 1

Interventions

Azacitidine 2venetoclax 1Vorinostat 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
GATA2 Deficiency × Lenalidomide × Classical hematology × Clear all
NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡